Literature DB >> 8104834

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

A Asplund-Carlson1, A Hamsten, B Wiman, L A Carlson.   

Abstract

Impaired fibrinolytic function secondary to elevated plasma plasminogen activator inhibitor-1 activity, hypertriglyceridaemia and hyperinsulinaemia are frequent findings in patients with coronary heart disease. It has been debated whether VLDL or insulin is the major regulator of plasma plasminogen activator inhibitor-1 activity. This study examines the relationships between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, fasting and post-oral glucose load insulin levels and insulin sensitivity, as estimated by the minimal model method. Subjects studied were randomly selected hypertriglyceridaemic (n = 65) and age-matched normotriglyceridaemic (n = 61) men, aged 40-50 years, recruited in a population survey. Plasma plasminogen activator inhibitor-1 activity was higher in the hypertriglyceridaemic than in the normotriglyceridaemic group (21 +/- 14 vs 10 +/- 8 mU/l; p < 0.01). The hypertriglyceridaemic group had higher serum insulin, basal as well as 2 h after intake of the oral glucose load, and a lower insulin sensitivity index. In univariate analysis, plasma plasminogen activator inhibitor-1 activity correlated positively with VLDL triglycerides in both the hyper- and normotriglyceridaemic groups (r = 0.43 r = 0.60, respectively) and negatively with the insulin sensitivity index (r = -0.35 r = -0.44, respectively). In multivariate analysis, VLDL triglyceride levels were found to be independently related to plasma plasminogen activator inhibitor-1 activity in both groups, whereas insulin sensitivity/serum insulin levels were not. An unexpected finding was that the serum activity of the enzyme gamma glutamyl transpeptidase appeared to influence the relationships for plasma plasminogen activator inhibitor-1 in the hypertriglyceridaemic group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104834     DOI: 10.1007/bf00400356

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

1.  Relationship between blood fibrinoytic activity and body fatness.

Authors:  D A SHAW; D MACHAUGHTON
Journal:  Lancet       Date:  1963-02-16       Impact factor: 79.321

2.  "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes.

Authors:  P Björntorp
Journal:  Arteriosclerosis       Date:  1990 Jul-Aug

3.  Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.

Authors:  I Juhan-Vague; C Roul; M C Alessi; J P Ardissone; M Heim; P Vague
Journal:  Thromb Haemost       Date:  1989-06-30       Impact factor: 5.249

4.  Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden.

Authors:  I B Sundell; T K Nilsson; M Rånby; G Hallmans; G Hellsten
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

5.  Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.

Authors:  I B Sundell; T K Nilsson; G Hallmans; G Hellsten; G H Dahlén
Journal:  Atherosclerosis       Date:  1989-11       Impact factor: 5.162

6.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

Authors:  J Mehta; P Mehta; D Lawson; T Saldeen
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

7.  Dietary regulation of fibrinolytic factors.

Authors:  M Mehrabian; J B Peter; R J Barnard; A J Lusis
Journal:  Atherosclerosis       Date:  1990-09       Impact factor: 5.162

8.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

9.  Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL, and HDL levels. A population-based study.

Authors:  M Modan; H Halkin; A Lusky; P Segal; Z Fuchs; A Chetrit
Journal:  Arteriosclerosis       Date:  1988 May-Jun

10.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

View more
  12 in total

1.  Elevated expression of transforming growth factor-beta in adipose tissue from obese mice.

Authors:  F Samad; K Yamamoto; M Pandey; D J Loskutoff
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

Review 2.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

3.  Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

Authors:  F Samad; D J Loskutoff
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

Review 4.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

5.  Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study.

Authors:  Maria Franzini; Irene Fornaciari; Jian Rong; Martin G Larson; Claudio Passino; Michele Emdin; Aldo Paolicchi; Ramachandran S Vasan
Journal:  Clin Chim Acta       Date:  2012-12-14       Impact factor: 3.786

6.  Adipose Gene Expression Profile Changes With Lung Allograft Reperfusion.

Authors:  David J Lederer; Jason D Christie; Joshua M Diamond; Selim Arcasoy; Jamiela A McDonnough; Joshua R Sonett; Matthew Bacchetta; Frank D'Ovidio; Edward Cantu; Christian A Bermudez; Amika McBurnie; Melanie Rushefski; Laurel H Kalman; Michelle Oyster; Carly D'Errico; Yoshikazu Suzuki; Jon T Giles; Anthony Ferrante; Matthew Lippel; Gopal Singh
Journal:  Am J Transplant       Date:  2016-08-18       Impact factor: 8.086

7.  Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight.

Authors:  Jeffrey R Holzberg; Ran Jin; Ngoc-Anh Le; Thomas R Ziegler; Elizabeth M Brunt; Craig J McClain; Juna V Konomi; Gavin E Arteel; Miriam B Vos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-06       Impact factor: 2.839

8.  Tissue factor gene expression in the adipose tissues of obese mice.

Authors:  F Samad; M Pandey; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 9.  Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease.

Authors:  Christopher J Womack; Paul R Nagelkirk; Adam M Coughlin
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

10.  Sphingosine 1-phosphate distribution in human plasma: associations with lipid profiles.

Authors:  Samar M Hammad; Mohammed M Al Gadban; Andrea J Semler; Richard L Klein
Journal:  J Lipids       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.